Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Hq7.0
Hydroquinone – Forschung
Überwiegend Mechanismus / Beobachtung
8 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Hydroquinone sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus gemischt-qualitativen Meta-Analysen und randomisierten Studien, veröffentlicht 2003–2024 mit einer typischen Studiengröße von 40 Teilnehmenden.
Basierend auf 8 Studien · 1 Meta-Analyse · 2 RCTs · 682 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Nach Outcome
Skin tone & pigmentationGoldstandard zur Reduktion von Melasma und Hyperpigmentierung (verschreibungspflichtig; zeitlich begrenzt und unter Kontrolle anwenden) · 8-12 Wochen
Überwiegend Mechanismus / Beobachtung6 Studien
Safety profile
Zu wenige bewertete Studien2 Studien
Anemia & hematology
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
3 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024
200320132024
1Meta-Analyse2024
Cysteamine 5% was more effective than placebo in reducing the Melasma Area and Severity Index (SMD - 0.84; 95% CI - 1.19, - 0.49, p < 0.00001, I2 = 0%), but showed no significant difference when compared with hydroquinone 4% (SMD 0.16; 95% CI - 0.22, 0.53, p = 0.42).
Mawu FO, Christopher PM. · Arch Dermatol Res (2024)
RCT-only meta-analysis of 7 trials comparing cysteamine 5% with placebo or hydroquinone
Significantly more effective than placebo (SMD -0.84, I²=0%), but no significant difference vs hydroquinone 4% (non-superiority)
Adverse events higher than placebo but similar to hydroquinone — a comparable, not superior, alternative
Significantly more of the patients treated with RA+HQ+FA (26.1%) experienced complete clearing compared with the other treatment groups (4.6%) at the end of week 8 (P<.0001).
Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, Menter A, Baumann L, Wieder JJ, Jarratt MM, Pariser D, Martin D, Weiss J, Shavin J, Ramirez N. · Cutis (2003)
Two pooled 8-week multicenter randomized investigator-blind trials (n=641) of the triple-combination (tretinoin 0.05% + hydroquinone 4% + fluocinolone 0.01%) vs the three dual pairings
Complete clearing at week 8: 26.1% (triple) vs 4.6% (dual combinations), P<.0001; >75% reduction in >70% of triple-combination patients
Most common adverse reactions were erythema, peeling, burning, and stinging, mostly mild
3Systematische Übersicht2014
Triple-combination cream (hydroquinone, tretinoin, and fluocinolone acetonide) was more effective at lightening melasma than hydroquinone alone (relative risk 1.58, 95% confidence interval 1.26-1.97) or any of the agents in a dual-combination cream.
Jutley GS, Rajaratnam R, Halpern J, Salim A, Emmett C. · J Am Acad Dermatol (2014)
Abridged Cochrane review of 20 RCTs (2125 participants) across 23 melasma treatments
Triple-combination outperformed hydroquinone alone (RR 1.58) and all dual combinations; azelaic acid 20% beat 2% hydroquinone
Evidence limited by poor methodology, non-standardized outcomes, and short duration
Kligman's trio (KT), combining hydroquinone, retinoic acid and corticosteroid, is considered as the gold standard treatment of melasma. Its efficacy has never been matched before.
Bertold C, Fontas E, Singh T, Gastaut N, Ruitort S, Wehrlen Pugliese S, Passeron T. · J Eur Acad Dermatol Venereol (2023)
24-week double-blind RCT (n=40) using Kligman's trio (hydroquinone + retinoic acid + corticosteroid) as the active gold-standard comparator
Kligman's trio produced a significant mMASI reduction of -2.84 at 12 weeks (p<0.0002)
Notes the hydroquinone gold standard's efficacy 'has never been matched,' though tempered by frequent adverse effects
All the skin lighteners examined showed marked increases in TYR, COX1, and FTH1 gene and protein expression, but not in MC1R expression in melanocytes.
Gruber JV, Holtz R. · Oxid Med Cell Longev (2013)
In-vitro study of hydroquinone, kojic acid, and niacinamide on cultured melanocytes/keratinocytes
All three altered TYR, COX1, and ferritin (FTH1) expression, implicating iron handling in melanin synthesis
Authors note the precise mechanisms of these lighteners remain incompletely understood
Many of the well-known depigmenting agents such as hydroquinone and 4-hydroxyanisole are, in fact, melanocytotoxic chemicals which are oxidized in melanocytes to produce highly toxic compounds such as quinones.